RAPT Therapeutics Inc Cash Flow-to-Debt Ratio
RAPT Therapeutics Inc cash flow-to-debt ratio. RAPT Therapeutics Inc (RAPT) has a Cash Flow-to-Debt Ratio of -0.91x as of September 2025, meaning its operating cash flow of $-12.46 Million could theoretically repay -1% of its total liabilities ($13.76 Million) in one year. See RAPT Therapeutics Inc free cash flow to debt ratio to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of RAPT Therapeutics Inc (2017–2024)
Cash flow-to-debt ratio of RAPT Therapeutics Inc from 2017 to 2024. Historical debt coverage capacity for RAPT Therapeutics Inc across 8 annual periods. Also explore RAPT Therapeutics Inc annual equity growth to track the company's year-over-year net asset growth rate.
RAPT Therapeutics Inc Cash Flow-to-Debt Ratio by Year (2017–2024)
RAPT Therapeutics Inc cash flow-to-debt ratio by year from 2017 to 2024. Year-by-year debt coverage analysis for RAPT Therapeutics Inc. For the full cash flow conversion analysis, see cash efficiency ratio of RAPT Therapeutics Inc.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | -1.65x | $-83.30 Million | $50.42 Million | ▲ +55.2% |
| 2023 | -3.69x | $-97.05 Million | $26.29 Million | ▼ -9.7% |
| 2022 | -3.36x | $-70.77 Million | $21.04 Million | ▲ +32.5% |
| 2021 | -4.98x | $-61.03 Million | $12.26 Million | ▼ -81.9% |
| 2020 | -2.74x | $-40.49 Million | $14.79 Million | ▲ +11.4% |
| 2019 | -3.09x | $-35.47 Million | $11.48 Million | ▲ +47.4% |
| 2018 | -5.87x | $-32.95 Million | $5.61 Million | ▼ -2341.9% |
| 2017 | -0.24x | $-27.12 Million | $112.80 Million | — |